Disposal of non-core equine treatment for €1.3m

4th Apr by Equity Development

0 comments 199 reads

ECO Animal Health (LON:EAH) has announced the disposal of its treatment for equine parasitic infections, ECOmectin^® Horsepaste, to its long-term Italian manufacturing partner, ACME Drugs S.r.l. ACME will acquire all ECOmectin^® Horsepaste intellectual property, manufacturing and inventory, distribution and marketing.

Our Fair Value range remains 137p-146p which contrasts with the current share price, suggesting that the potential contribution to earnings from the product development pipeline deserves far closer attention.

https://www.equitydevelopment....

Unlock with Email

Unlock with Google

Already have an account?
Login here

About the Author

Equity Development

Premium Member

Equity Development Limited is regulated by the Financial Conduct Authority Disclaimer Equity Development Limited (‘ED’) is retained to act as financial adviser for its corporate clients, some or all of whom may now or in the future have an interest in the contents of this document. ED produces and distributes research for these corporate clients to persons who are not clients of ED. In the preparation of this report ED has taken professional efforts to ensure that the facts stated herein are clear, fair and not misleading, but makes no guarantee as to the accuracy or completeness of the information or opinions contained herein. This document has not been approved for the purposes of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom (‘FSMA’). Any reader of this research should not act or rely on this document or any of its contents. This report is being provided by ED to provide background information about the subject of the research to relevant persons, as defined by the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. Research produced and distributed by ED on its client companies is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent as defined by the FCA but is ‘objective’ in that the authors are stating their own opinions. This document is prepared for clients under UK law. In the UK, companies quoted on AIM are subject to lighter due diligence than shares quoted on the main market and are therefore more likely to carry a higher degree of risk than main market companies. ED may in the future provide, or may have in the past provided, investment banking services to the subject of this report. ED, its Directors or persons connected may at some time in the future have, or have had in the past, a material investment in the Company. ED, its affiliates, officers, directors and employees, will not be liable for any loss or damage arising from any use of this document to the maximum extent that the law permits. More information is available on our website www.equitydevelopment.co.uk more »

0 comments

Be the first to comment by using the form above.

Unlock the metrics for all these stocks and more...

Take a free trial

Facebook Twitter Youtube Instagram RSS

This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.

Unlock the metrics for all these stocks and more...

Take a free trial

Disposal of non-core equine treatment for €1.3m

Unlock the rest of this article with a 14 day trial

About the Author

Equity Development

0 comments

Unlock the metrics for all these stocks and more...

Unlock the metrics for all these stocks and more...